The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent

Biochemical and Biophysical Research Communications

Volumn 476, Issue 4, 2016, Pages 260-266

  Zhang, Qiangbo ^a   Wang, Hong ^b   Ran, Lin ^a   Zhang, Zongli ^a   Jiang, Runde ^a  

^a SHANDONG UNIVERSITY   (China)

^b WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Akt Erk signaling; Chemosensitization; Gemcitabine; Pancreatic cancer; TIC10; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TIC10; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; MESSENGER RNA; TIC10 COMPOUND; TNFSF10 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL; TREATMENT DURATION; TUMOR VOLUME; XENOGRAFT; ANIMAL; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; METABOLISM; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; MAP KINASE SIGNALING SYSTEM; MICE, SCID; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84973137572     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.05.106     Document Type: Article

References (35)

1. [1] Costello, E., Neoptolemos, J.P., Pancreatic cancer in 2010: new insights for early intervention and detection. Nat. Rev. Gastroenterol. Hepatol. 8 (2011), 71–73.
2. [2] Hidalgo, M., Pancreatic cancer. N. Engl. J. Med. 362 (2010), 1605–1617.
3. [3] Ducreux, M., Boige, V., Malka, D., Treatment of advanced pancreatic cancer. Semin. Oncol. 34 (2007), S25–S30.
4. [4] Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., Gutberlet, K., Kettner, E., Schmalenberg, H., Weigang-Koehler, K., Bechstein, W.O., Niedergethmann, M., Schmidt-Wolf, I., Roll, L., Doerken, B., Riess, H., Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 297 (2007), 267–277.
5. [5] Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., Seay, T., Tjulandin, S.A., Ma, W.W., Saleh, M.N., Harris, M., Reni, M., Dowden, S., Laheru, D., Bahary, N., Ramanathan, R.K., Tabernero, J., Hidalgo, M., Goldstein, D., Van Cutsem, E., Wei, X., Iglesias, J., Renschler, M.F., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369 (2013), 1691–1703.
6. [6] Blaszkowsky, L., Treatment of advanced and metastatic pancreatic cancer. Front. Biosci. 3 (1998), E214–E225.
7. [7] Johnstone, R.W., Frew, A.J., Smyth, M.J., The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8 (2008), 782–798.
8. [8] Allen, J.E., Krigsfeld, G., Mayes, P.A., Patel, L., Dicker, D.T., Patel, A.S., Dolloff, N.G., Messaris, E., Scata, K.A., Wang, W., Zhou, J.Y., Wu, G.S., El-Deiry, W.S., Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci. Transl. Med., 5, 2013 171ra117.
9. [9] Ghaffari, S., Jagani, Z., Kitidis, C., Lodish, H.F., Khosravi-Far, R., Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 6523–6528.
10. [10] Prabhu, V.V., Allen, J.E., Dicker, D.T., El-Deiry, W.S., Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal Cancer stem-like cells in an akt/Foxo3a/TRAIL-dependent manner. Cancer Res. 75 (2015), 1423–1432.
11. [11] Wagner, J., Kline, C.L., Pottorf, R.S., Nallaganchu, B.R., Olson, G.L., Dicker, D.T., Allen, J.E., El-Deiry, W.S., The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget 5 (2014), 12728–12737.
12. [12] Zhang, J., Hong, Y., Shen, J., Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo. Tumour Biol. 36 (2015), 5699–5706.
13. [13] Zhu, Y.R., Xu, Y., Fang, J.F., Zhou, F., Deng, X.W., Zhang, Y.Q., Bufotalin-induced apoptosis in osteoblastoma cells is associated with endoplasmic reticulum stress activation. Biochem. Biophys. Res. Commun. 451 (2014), 112–118.
14. [14] Chang, C.C., Liao, Y.S., Lin, Y.L., Chen, R.M., Nitric oxide protects osteoblasts from oxidative stress-induced apoptotic insults via a mitochondria-dependent mechanism. J. Orthop. Res. 24 (2006), 1917–1925.
15. [15] Meeran, S.M., Katiyar, S., Katiyar, S.K., Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol. Appl. Pharmacol. 229 (2008), 33–43.
16. [16] Zhen, Y.F., Wang, G.D., Zhu, L.Q., Tan, S.P., Zhang, F.Y., Zhou, X.Z., Wang, X.D., P53 dependent mitochondrial permeability transition pore opening is required for dexamethasone-induced death of osteoblasts. J. Cell Physiol. 229 (2014), 1475–1483.
17. [17] Wu, W., Zou, M., Brickley, D.R., Pew, T., Conzen, S.D., Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. Mol. Endocrinol. 20 (2006), 2304–2314.
18. [18] Chen, B., Xu, M., Zhang, H., Xu, M.Z., Wang, X.J., Tang, Q.H., Tang, J.Y., The antipancreatic Cancer activity of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2. DNA Cell Biol. 34 (2015), 610–617.
19. [19] Bhagwat, S.V., Gokhale, P.C., Crew, A.P., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J., Bittner, M., Dudkin, L., Epstein, D.M., Gibson, N.W., Wild, R., Arnold, L.D., Houghton, P.J., Pachter, J.A., Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol. Cancer Ther. 10 (2011), 1394–1406.
20. [20] Allen, J.E., Crowder, R., El-Deiry, W.S., First-in-class small molecule ONC201 induces DR5 and cell death in tumor but not normal cells to provide a wide therapeutic index as an Anti-Cancer agent. PLoS One, 10, 2015, e0143082.
21. [21] Porter, A.G., Janicke, R.U., Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6 (1999), 99–104.
22. [22] Ishizawa, J., Kojima, K., Chachad, D., Ruvolo, P., Ruvolo, V., Jacamo, R.O., Borthakur, G., Mu, H., Zeng, Z., Tabe, Y., Allen, J.E., Wang, Z., Ma, W., Lee, H.C., Orlowski, R., Sarbassov dos, D., Lorenzi, P.L., Huang, X., Neelapu, S.S., McDonnell, T., Miranda, R.N., Wang, M., Kantarjian, H., Konopleva, M., Davis, R.E., Andreeff, M., ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci. Signal, 9, 2016 ra17.
23. [23] Kline, C.L., Van den Heuvel, A.P., Allen, J.E., Prabhu, V.V., Dicker, D.T., El-Deiry, W.S., ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2alpha kinases. Sci. Signal, 9, 2016 ra18.
24. [24] Endo Greer, Y., Lipkowitz, S., ONC201: stressing tumors to death. Sci. Signal, 9, 2016 fs1.
25. [25] Furukawa, T., Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. J. Gastroenterol. 43 (2008), 905–911.
26. [26] Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., Mills, G.B., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005), 988–1004.
27. [27] Vivanco, I., Sawyers, C.L., The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002), 489–501.
28. [28] Akinleye, A., Iragavarapu, C., Furqan, M., Cang, S., Liu, D., Novel agents for advanced pancreatic cancer. Oncotarget 6 (2015), 39521–39537.
29. [29] Baer, R., Cintas, C., Therville, N., Guillermet-Guibert, J., Implication of PI3K/Akt pathway in pancreatic cancer: when PI3K isoforms matter?. Adv. Biol. Regul. 59 (2015), 19–35.
30. [30] Seicean, A., Petrusel, L., Seicean, R., New targeted therapies in pancreatic cancer. World J. Gastroenterol. 21 (2015), 6127–6145.
31. [31] Agarwal, A., Saif, M.W., KRAS in pancreatic Cancer. JOP 15 (2014), 303–305.
32. [32] Bryant, K.L., Mancias, J.D., Kimmelman, A.C., Der, C.J., KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 39 (2014), 91–100.
33. [33] Heinemann, V., Boeck, S., Hinke, A., Labianca, R., Louvet, C., Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 8, 2008, 82.
34. [34] Moore, M.J., Goldstein, D., Hamm, J., Figer, A., Hecht, J.R., Gallinger, S., Au, H.J., Murawa, P., Walde, D., Wolff, R.A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., Parulekar, W., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25 (2007), 1960–1966.
35. [35] Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA Cancer J. Clin. 64 (2014), 9–29.